Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569197 | 0.83 | L3MBTL1 (0.67) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL2764261 | 0.82 | L3MBTL1 (0.65) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL788538 | 0.82 | L3MBTL1 (0.65) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL15882461 | 0.79 | L3MBTL1 (0.61) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL14026306 | 0.76 | L3MBTL1 (0.57) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL12960906 | 0.72 | L3MBTL1 (0.52) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL2766749 | 0.72 | L3MBTL1 (0.53) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL2764206 | 0.72 | L3MBTL1 (0.53) | L3MBTL1POLBMAPTTP53PPARG | |
| SCHEMBL971957 | 0.72 | POLB (0.65) | L3MBTL1POLBMAPTTP53PPARG | |
| Hydrochloric Acid SCHEMBL2766753 | 0.71 | L3MBTL1 (0.52) | L3MBTL1POLBMAPTTP53PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | L3MBTL1 4497/4885POLB 421/4885MAPT 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.